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AbSTrACT
Objectives Genetic variations in TNFAIP3 (a20) de-
ubiquitinase (DUB) domain increase the risk of systemic 
lupus erythematosus (sle) and rheumatoid arthritis. a20 
is a negative regulator of nF-κB but the role of its DUB 
domain and related genetic variants remain unclear. We 
aimed to study the functional effects of a20 DUB-domain 
alterations in immune cells and understand its link to sle 
pathogenesis.
Methods crisPr/cas9 was used to generate human 
U937 monocytes with a20 DUB-inactivating C103A 
knock-in (Ki) mutation. Whole genome rna-sequencing 
was used to identify differentially expressed genes 
between WT and C103A Ki cells. Functional studies were 
performed in a20 C103A U937 cells and in immune cells 
from a20 C103A mice and genotyped healthy individuals 
with a20 DUB polymorphism rs2230926. neutrophil 
extracellular trap (neT) formation was addressed ex vivo 
in neutrophils from a20 C103A mice and sle-patients 
with rs2230926.
results Genetic disruption of a20 DUB domain in 
human and murine myeloid cells did not give rise to 
enhanced nF-κB signalling. instead, cells with C103A 
mutation or rs2230926 polymorphism presented an 
upregulated expression of PADI4, an enzyme regulating 
protein citrullination and neT formation, two key 
mechanisms in autoimmune pathology. a20 C103A 
cells exhibited enhanced protein citrullination and 
extracellular trap formation, which could be suppressed 
by selective PaD4 inhibition. Moreover, sle-patients 
with rs2230926 showed increased neTs and increased 
frequency of autoantibodies to citrullinated epitopes.
Conclusions We propose that genetic alterations 
disrupting the a20 DUB domain mediate increased 
susceptibility to sle through the upregulation of PADI4 
with resultant protein citrullination and extracellular trap 
formation.
InTrOduCTIOn
A20 (encoded by TNFAIP3) is a negative regu-
lator of NF-κB-induced expression of proinflam-
matory and survival genes. Several studies have 
shown that individuals with the non-synonymous 
polymorphism rs2230926 located in the A20 
de-ubiquitinase (DUB) domain (phenylala-
nine-to-cysteine change at position 127, F127C), 
have increased susceptibility to autoimmune 
diseases, such as systemic lupus erythematosus 
(SLE) and rheumatoid arthritis (RA).1–3 Other 
coding polymorphisms and alternative splicing 
isoforms affecting the A20 DUB domain are also 
associated with autoimmune diseases.4 5 DUB-do-
main polymorphisms are considered to lead to 
structural changes, reduced DUB activity and 
increased NF-κB activity,1 4 but recent studies 
Key messages
What is already known about this subject?
 ► A20 is a well-known negative regulator of NF-
κB, and genetic variations in its de-ubiquitinase 
(DUB) domain, such as rs2230926, are 
associated with increased risk of rheumatoid 
arthritis and systemic lupus erythematosus 
(SLE).
 ► The functional role of genetic alterations in A20 
DUB domain is unclear and studies around NF-
κB-independent mechanisms are lacking.
What does this study add?
 ► This study reveals a novel functional mechanism 
of A20 DUB domain disruptions and provides 
a new genetic link to protein citrullination and 
extracellular traps in SLE via an upregulation of 
PADI4.
 ► Our results highlight the importance of protein 
citrullination and neutrophil extracellular traps 
in SLE pathogenesis.
How might this impact on clinical practice or 
future developments?
 ► Our results support a role for PAD4 and protein 
citrullination in SLE pathogenesis and suggest 
PAD4 as a potential therapeutic target in 
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question the role of the A20 DUB domain in NF-κB regula-
tion.6 Although mice with the C103A mutation (cysteine-to-al-
anine change at position 103 of A20) lack a functional DUB 
domain,6–9 De et al6 reported that their innate immune cells 
show comparable NF-κB-mediated proinflammatory response 
to wild-type (WT) mice and suggest that the DUB activity of 
A20 is not necessary for its NF-κB-inhibiting function. Thus, 
other mechanisms beyond the NF-κB pathway could be respon-
sible for the increased risk of autoimmunity caused by genetic 
disruption of the A20 DUB domain.
Here, we show that instead of activating the NF-κB pathway, 
genetic disruptions in A20 DUB domain unexpectedly lead 
to increased protein citrullination. Protein citrullination is a 
post-translational modification converting the amino acid argi-
nine into a citrulline on target proteins. This modification is 
catalysed by a group of Ca2+-dependent enzymes called peptidyl 
arginine deiminases (PADs).10 Citrullination is a key feature in 
RA pathogenesis where it is linked to the induction of autoan-
tibodies to citrullinated self-epitopes (reviewed in Catrina et 
al11). Additionally, histone citrullination by PAD4 is involved 
in NET formation, a process whereby neutrophils release chro-
matin filaments coated with citrullinated histones and antibac-
terial proteins to trap and kill pathogens.12 13 In SLE, enhanced 
NET formation has been reported and suggested to contribute 
the pathogenesis by different mechanisms, such as promoting 
autoantibody formation to post-translationally modified nuclear 
antigens,14 15 stimulating release of type I IFNs from plasmacy-
toid DCs,16 17 and mediating endothelial dysfunction, prothrom-
botic and atherosclerotic changes.18–21
Here, we explored the functional effects of genetic disruptions 
in A20 DUB domain using a CRISPR/Cas9-generated human 
cell line with C103A knock-in (KI) mutation, murine immune 
cells from A20 C103A mice, and immune cells from healthy 
individuals and SLE-patients carrying A20 DUB domain poly-
morphism rs2230926. We show that genetic disruptions in A20 
DUB domain cause upregulation of PADI4, leading to increased 
protein citrullination and extracellular trap formation. Our 
findings reveal a novel function for A20 DUB domain variants 
and provides a genetic link emphasising the role of citrullina-
tion, extracellular traps and neutrophils as upstream pathogenic 
mechanisms in SLE.
MeTHOdS
SLe-patients and healthy controls
SLE-patients were recruited at the rheumatology clinics in 
Uppsala, Karolinska (Stockholm), Lund and Linköping Univer-
sity Hospitals and from the four northern-most counties in 
Sweden. Medical records were reviewed; all patients were exam-
ined by a rheumatologist and fulfilled ≥4 American College of 
Rheumatology 1982 classification for SLE.22 Control individ-
uals were blood donors from Uppsala Bioresource, recruited 
at the Department of Transfusion Medicine, Uppsala Univer-
sity Hospital, Sweden. The study was approved by the regional 
ethics review boards of Uppsala, Lund, Linköping, Stockholm 
and Umeå and all participants gave their informed consent. 
Demographics of patients and controls are described in online 
supplementary table S1.
Patient and public involvement
The research included in this manuscript was conducted and 
designed without patient or public involvement on study design, 
outcomes or interpretation of results.
Generation of A20 C103A KI and A20 KO cells by CrISPr/Cas9
Online supplementary figure S1 represents the outline of the 
generation of C103A KI and A20 KO cells. Targeted KI muta-
tion C103A was generated by TG-to-GC substitution in human 
TNFAIP3 DUB domain (replacing cysteine at position 103 for 
alanine) using CRISPR/Cas9 in U937 cells. Guide RNAs were 
designed using the ZiFiT software (http:// zifit. partners. org/ 
ZiFiT/) and cloned into a pCas9-GFP expression vector. C103A 
cell clones were selected using green fluorescent protein (GFP) 
expression and restriction fragment length polymorphism and 
confirmed with sanger sequencing and droplet digital PCR. 
Three successfully generated homozygous C103A KI clones 
(C103A KI1-KI3) were confirmed deriving from two different 
guide RNAs to account for possible off-target effects. Control 
cells underwent the same processes as the targeted cells but in 
absence of plasmids. A20 knock-out (KO) cells were generated 
by transfecting U937 cells with the Cas9 expression vector 
coding the same guide RNAs as previously described, but in the 
absence of targeting vector and were screened for the absence of 
A20 protein by western blot.
neutrophil isolation
Blood from SLE-patients was collected in vacutainer tubes 
with heparin (BD Bioscience) and neutrophils were separated 
using density gradient centrifugation in LymphoPrep (StemCell 
Technologies) after erythrocyte sedimentation in 2% Dextran 
(Sigma). Purity was >95% as assessed by Sysmex XT 1800i 
(Sysmex Kobe, Japan). Murine neutrophils were isolated from 
whole blood from 8 to 12-week-old sex-matched WT and A20 
C103A KI mice using EasySep Mouse Neutrophil Enrichment 
Kit (Stemcell Technologies) after erythrocyte lysis with BD 
Pharm Lyse lysing solution (BD Bioscience). Blood from 3 to 5 
mice were pooled together in each experiment to obtain enough 
neutrophils. Experiments with human and murine neutrophils 
were performed in RPMI with 10% FBS (Gibco).
neT induction and immunofluorescence staining
Equal number of neutrophils were plated in eight-well chamber 
glass slides (Lab-Tek II Chamber Slide, NUNC) precoated with 
Poly-L-lysine (Sigma-Aldrich). PAD4 inhibitor GSK484 (10 µM) 
or vehicle (dimethyl sulfoxide (DMSO)) were added to the cells 
30 min before stimulation with 1 or 4 µM Ionomycin +2 mM 
CaCl2. After 1 hour and 45 min for murine neutrophils, or after 
1 hour for human neutrophils, cells were fixed in 4% parafor-
maldehyde (VWR Chemicals), permeabilised with 0.25% Triton 
X-100 (Sigma), and blocked in 1% BSA/2% goat serum. Cells 
were stained with antibodies against citrullinated histone H3 
(ab5103; Abcam) and Myeloperoxidase (clone 2C7, ab25989; 
Abcam) followed by Goat anti-Rabbit IgG (H+L, Alexa Fluor 
568; Thermo Fisher Scientific) and Goat anti-Mouse IgG 
(H+L, Alexa Fluor 633; Thermo Fisher Scientific) secondary 
antibodies. Nuclei and DNA were visualised by Hoechst (Life 
technologies) and SYTOX Green Nucleic Acid Stain (Thermo 
Fisher Scientific). Fluorescence microscopy was performed using 
Carl Zeiss LSM 880 confocal microscope and images analysed 
by ZEN v.2.3 software. See online supplementary figure S9C-D 
for control stainings. Researchers were blinded to the patient 
genotype when performing experiments and analysis.
detection of secreted citrullinated histone H3 and dsdnA
The supernatant from U937 cells and primary neutrophils was 
collected after 6 or 1 hour after Ionomycin treatment, respec-
tively. Double-stranded DNA (dsDNA) was measured using 
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Figure 1 Genetic disruption of A20 de-ubiquitinase (DUB) domain does not lead to enhanced NF-ĸB activation. (A) Generation of A20 C103A 
knock-in (KI) mutation in U-937 cell line using CRISPR/Cas9. Three different homozygote C103A KI clones were generated and Sanger sequencing 
of the homozygote clones is shown to the right. (B) RNA sequencing data from lipopolysaccharide (LPS)-stimulated human U-937 cells (A20 WT, 
knock-out (KO) and C103A KI) were analysed using gene set enrichment analysis (GSEA). NF-ĸB target genes were significantly enriched in A20 KO 
cells (left), but not in A20 C103A KI cells (right), when compared with their wild-type counterparts. (C) Peripheral blood mononuclear cells (PBMCs) 
from individuals with A20 DUB polymorphism rs2230926 (n=10, CA or CC) or without (n=7, AA), were treated with LPS for 6 hours and intracellular 
staining of tumour necrosis factor-alpha and IL-6 was measured by flow cytometry in monocytes (CD14 Mo and CD16 Mo) and myeloid dentritic 
cells (mDC). No significant differences were found between genotypes using a two-tailed t-test. CA represents individuals that are heterozygous 
for rs2230926 risk polymorphism, CC are homozygous and AA represents individuals without rs2230926 risk allele. FDR, false discovery rate; NES, 
normalised enrichment score; OTU, ovarian tumour domain; ZF, zinc finger.





(n=1980) P value Or (95% CI)
rs2230926 (all) 6.42% 3.49% 1.00×10−6 1.83 (1.44 to 2.33)
  Females only 5.79% 3.55% 5.71×10−4 1.62 (1.23 to 2.13)
  Males only 10.37% 3.29% 1.27*10−5 3.26 (1.92 to 5.54)
MAF, minor allele frequency; SLE, systemic lupus erythematosus.
Quant-iT PicoGreen dsDNA reagent (Invitrogen). For detec-
tion of citrullinated histone H3, the proteins in the supernatant 
were precipitated with 20% trichloroacetic acid (Sigma-Aldrich), 
resuspended in 2,5x LDS loading buffer (Invitrogen) and anal-
ysed by western blotting.
Statistical analyses
All data are represented as mean+SD unless otherwise indicated. 
Figure legends specify the type of statistical test used in different 
experiments. Graphpad Prism (v7) was used for statistical anal-
yses of in vitro data. One-tailed comparisons were used when 
confirming a previously observed effect, otherwise two-tailed 
comparisons were performed. Pairwise comparison was used 
if inter-experimental baseline signals differed substantially, 
and is then specified in the figure legend. For statistical anal-
yses of large data sets, statistical details are described in corre-
sponding method sections. P values below 0.05 were considered 
significant.
Detailed information for all methods can be found in online 
supplementary material.
reSuLTS
A20 dub-domain disruption does not increase nF-κb 
activation
To address the functional effect of A20 DUB-disruption in devel-
opment of autoimmunity, we used CRISPR/Cas9 genome-ed-
iting to introduce the DUB-inactivating C103A mutation into the 
human U937 monocytic cell line (C103A KI cells, figure 1A and 
online supplementary figure S1). We performed whole transcrip-
tome analysis in WT, C103A KI and A20 KO U937 cells. When we 
analysed the expression of known NF-κB target genes23 by Gene 
Set Enrichment Analysis, we found that while a complete A20 KO 
caused a significant increase in NF-κB target gene expression on 
LPS-stimulation, C103A KI cells did not demonstrate enhanced 
NF-κB signalling (figure 1B). Moreover, we observed no alter-
ation in TLR-induced NF-κB signalling in bone marrow derived 
macrophages (BMDMs) from C103A KI mice (online supple-
mentary figure S2), supporting published data indicating that the 
C-terminal zinc fingers, and not the DUB domain, are involved in 
NF-κB signalling.6 24
Next, we asked whether the A20 DUB-domain polymorphism 
rs2230926 interferes with NF-κB activation. We genotyped 
982 SLE-patients and 1980 healthy individuals from a Swedish 
SLE cohort (online supplementary table S1) and in agreement 
with earlier studies,1 3 we found that rs2230926 associated with 
SLE (table 1, OR=1.83, p=1×10−6). Additionally, we found it 
being an even stronger risk factor for SLE in males (OR=3.26, 
p=1.27×10−5). We used flow cytometry to measure the levels 
of IL-6 and tumour necrosis factorα, two NF-κB-induced cyto-
kines regulated by A20, in LPS-stimulated monocytes and myeloid 
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Figure 2 A20 de-ubiquitinase (DUB) domain disruption leads to PADI4 over expression. (A) Confirmation of RNAseq data using qPCR analysis of 
the expression of PADI4 mRNA in U937 wild-type (WT) (n=4), A20 knock-out (KO) (n=4) and A20 C103A knock-in (KI) cells (n=3). Individual squares 
or circles represent individual CRISPR/Cas9-generated cell clones. (B) PAD4 protein expression measured by western blot in DMSO-treated individual 
U937 WT and C103A KI clones. (C) qPCR analysis of the expression of murine PADI4 mRNA in BMDMs from WT and A20 C103A KI mice (n=3 per 
group). (D) qPCR analysis of the expression of PADI4 mRNA in human PBMCs (n=13 AA, n=13 CA). (E) qPCR analysis of the expression of PADI4 
in PBMC-derived human monocytes (left graph, n=9 AA, n=13 CA). The right graph represent Western blot quantification of PAD4 protein relative 
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in PBMC-derived human monocytes (n=7 AA, n=6 CA). CA represents individuals that are 
heterozygous for rs2230926 risk polymorphism and AA represents individuals without rs2230926 risk allele. (A,C,D,E) PADI4 expression levels are 
normalised to house-keeping genes GUSB and ACTB and are represented as relative mRNA expression to average PADI4 expression in controls (WT 
or AA). Statistical differences between groups were calculated using two-tailed t-test with Welch correction (D) or non-parametric one-tailed Mann-
Whitney test (A,C,E). Bars represent mean+SD. *p<0.05, **p<0.01. BMDM, bone marrow derived macrophage.
dendritic cells from healthy individuals with rs2230926 risk variant 
(CA or CC) or without (AA). However, no difference could be 
observed between genotypes (figure 1C and online supplementary 
figure S3). The levels of A20 were similar in both groups (online 
supplementary figure S4). Together, these results indicate that the 
consequences of A20 DUB-domain genetic variants associated with 
autoimmunity are not mediated via enhanced NF-κB signalling.
Genetic A20 dub variants express elevated PADI4 levels
To explore other possible mechanisms regulated by the A20 
DUB-domain mutations, beyond NF-κB signalling, we compared 
the global gene expression profiles between A20 KO, C103A KI 
and WT U937-cells. We observed that unstimulated C103A KI 
cells presented a large number of differentially expressed genes 
compared with WT cells and KO cells (online supplementary 
table S2). One of the top hits of differentially expressed genes in 
C103A KI cells was PADI4, encoding PAD 4 (PAD4), while no 
PADI4 upregulation was observed in A20 KO cells (online supple-
mentary table S2). qPCR analysis showed around 30-fold PADI4 
upregulation in all C103A KI clones when compared with WT 
clones (figure 2A). This increased expression was also reflected at 
the protein level (figure 2B). PADI4 was also significantly elevated 
in C103A mouse BMDMs compared with WT, indicating that 
this effect is not restricted to the genetically modified U937-cells 
(figure 2C). We then analysed PADI4 expression in human PBMCs 
from healthy individuals with or without rs2230926 risk allele, 
and found significantly increased PADI4 levels in the subjects 
with rs2230926 risk allele (figure 2D). The difference in PADI4 
expression was confirmed in PBMC-derived monocytes and NK 
cells (figure 2E and online supplementary figure S5). PAD4 protein 
levels were measured by western blot in isolated monocytes and 
were also significantly higher in individuals with the rs2230926 
risk allele (figure 2E and online supplementary figure S6).
A20 dub-domain disruption enhances protein citrullination 
and neT formation
Given the strong link between citrullination and autoimmune 
pathologies, we were encouraged to explore the functional conse-
quences of PADI4 over expression caused by A20 DUB mutations. 
Flow-cytometric analysis with F95 pan-citrulline antibody showed 
increased protein citrullination in the C103A KI cells on PAD4 
activation with Ionomycin and CaCl2 when compared with WT 
cells (figure 3A). Protein citrullination in cells with mutated A20 is 
dependent on PAD4, as specific PAD4 inhibition with small-mole-
cule inhibitor GSK48412 decreased citrullination (figure 3B, online 
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Figure 3 Disruption of A20 de-ubiquitinase (DUB) domain is associated with PAD4-dependent increase in protein citrullination and release of 
nuclear antigens. (A–B) Total intracellular protein citrullination was measured in wild-type (WT) and C103A knock-in (KI) U937 cells using flow 
cytometry after stimulation with ionomycin. The effect of PAD4 inhibitor GSK484 on protein citrullination was assessed in U937 A20 C103A KI cells 
(B). Data points represent experimental duplicates in three independent experiments. (C) Western blot performed on supernatants from 1 million WT 
or A20 C103A KI U937 cells stimulated with ionomycin for 6 hours, with or without GSK484. GAPDH expression from the cell lysate is represented 
as an input control. representative blot from one out of four experiments. (D, E) Quantification of H3cit Western blot signal from four independent 
experiments is represented as mean H3cit density +SD. (F) the presence of cell free double stranded DNA (dsDNA) in the supernatants of U937 WT 
and KI cells were measured after 6 hours of ionomycin treatment. Results from four independent experiments are represented as mean % increase 
compared with unstimulated cells +SD. (G) The presence of dsDNA in the supernatants of unstimulated PBMCs derived from healthy individuals with 
the rs2230926 risk variant (CA) or without (AA). Statistical differences between groups were performed using paired two-tailed t-test (D–F), two-
tailed t-test (G) or paired two-tailed non-parametric Wilcoxon test (A,B). Unless different concentrations are stated, 4 µM ionomycin was used in the 
presence of 2 mM CaCl2. GSK484 was used at 10 µM. *p<0.05, **p<0.01, ***p<0.001.
supplementary figure S7). Next, we explored the role of A20 DUB 
variants on histone H3 citrullination (H3cit), NET formation and 
release of nuclear antigens linked to the pathogenesis of SLE. As 
extracellular trap formation is not restricted to neutrophils but is 
also seen in monocytes and macrophages,25 26 we used the U937 
cells to study these processes. We observed an increased cyto-
plasmic H3cit expression in the C103A KI cells while no differ-
ences were seen in nuclear levels of citrullinated histones between 
C103A KI and WT cells (online supplementary figure S8). As H3cit 
and dsDNA are released in the NET formation, we measured 
H3cit and dsDNA in the supernatant of Ionomycin-treated U937 
cells. C103A KI cells demonstrated increased levels of both H3cit 
and dsDNA on Ionomycin-treatment compared with the WT 
cells, and the levels decreased significantly on PAD4 inhibition 
(figure 3C–F). A trend to increased spontaneous dsDNA release 
was also seen in PBMCs from individuals with the rs2230926 risk 
allele (figure 3G).
Additionally, we studied Ionomycin-induced NET formation in 
neutrophils ex vivo, and quantified the number of H3cit-positive 
cells as a marker of NETs, as previously described.12 27 28 Iono-
mycin-treatment of blood-derived murine neutrophils led to NET 
generation characterised by increased H3cit expression and DNA 
spreading with H3cit/DNA co-localisation (online supplemen-
tary figure S9A). A higher percentage of H3cit-positive neutro-
phils was found in C103A KI mice than in WT mice, linking A20 
DUB-domain disruption to increased NET formation (figure 4A). 
Inhibition of PAD4 in murine neutrophils led to reduction of 
Ionomycin-induced NETs (figure 4B). Human neutrophils stimu-
lated with Ionomycin also formed NETs characterised by H3cit 
expression which co-localise with DNA and myeloperoxidase 
(online supplementary figure S9B). We next studied NET forma-
tion in neutrophils isolated from 12 genotyped SLE patients (six 
with the rs2230926 risk allele and six without). When stimulated 
with high-dose (4 µM) Ionomycin, most of the neutrophils under-
went full-blown NET-formation with extruding DNA chromatin 
fibres and H3cit expression (figure 4C). Ionomycin-induced NETs 
and release of H3cit could be prevented by PAD4 inhibition, 
confirming the central role of PAD4 in this process (figure 4C,D). 
In order to get a window for NET quantification, we used a lower 
dose of Ionomycin (1 uM) and quantified the number of H3cit-ex-
pressing neutrophils (figure 4E shows quantification and online 
supplementary figure S9E shows example images). Neutrophils 
from SLE-patients with rs2230926 risk allele expressed a higher 
percentage of H3cit positive cells than SLE-patients without risk 
allele. The higher propensity of NET formation in SLE-patients 
with rs2230926 was supported by increased number of neutro-
phils showing DNA extrusions and increased amount of secreted 
cell-free DNA in the neutrophil supernatants (online supplemen-
tary figure S10). Ionomycin-induced DNA extrusions in SLE-de-
rived neutrophils were further confirmed to show characteristic 
co-expression of DNA and myeloperoxidase (online supplemen-
tary figure S11).
A20 rs2230926 associates with presence of antibodies to 
citrullinated antigens in SLe
The presence of antibodies against citrullinated proteins (ACPA) is 
a hallmark of RA, but ACPA can also be detected in a small group 
of SLE-patients.29 Thus, we analysed antibodies to cyclic citrul-
linated peptides (CCP) in 195 SLE patients in our cohort, and 
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Figure 4 Disruption of A20 de-ubiquitinase (DUB) domain is associated with PAD4-dependent increase in NET formation. (A–C) Immunostaining 
and confocal microscopy of citrullinated H3 (H3cit, red) and DNA (SytoxGreen in green or Hoechst in blue) in murine and human neutrophils. Scale 
bar=50 µm. (A) Comparison of H3cit expression in Ionomycin-stimulated neutrophils from wild-type (WT) and C103A Ki mice. Results are expressed 
as mean percentage H3cit-postitive cells compared with total cell number +SD, and are pooled values from three independent experiments including 
totally 13 WT and 11 C103A KI mice. Each data point represents the mean of one experiment. (B) Neutrophils from C103A KI mice were pretreated 
with PAD4 inhibitor GSK484 or vehicle (DMSO) before NET-induction by ionomycin. Representative image. (C–E) Neutrophils from human systemic 
lupus erythematosus (SLE)-patients that were homozygous (CC, n=1),heterozygous (CA, n=5), or lacked (AA, n=6) rs2230926, were induced to form 
NETs in vitro. (C,D) Human SLE-derived neutrophils were pretreated with GSK484 or vehicle (DMSO) and NET formation was induced with 4 µM 
ionomycin. Representative images show reduced H3cit expression in GSK484-treated cells (C). H3cit was released in the supernatant on ionomycin 
stimulation of SLE-neutrophils and could be blocked by PAD4 inhibition (D). (E) Neutrophils from SLE-patients were treated with 1 µM ionomycin and 
the number of H3cit-positive cells was counted and represented as percentage compared with total cell number. Samples analysed on the same day 
are connected with a line. Statistical differences between groups were performed using a two-tailed t-test (A) or paired two-tailed t-test (based on 
age-matched patients from the same experiment) (H). Unless different concentrations are stated, 4 µM ionomycin was used in the presence of 2 mM 
CaCl2. GSK484 was used at 10 µM. *p<0.05, **p<0.01.




CA or CC AA P value Or (95% CI)
IgM aCL 10 (19%) 96 (22%) ns 0.85 (0.44 to 1.65)
IgG aCL 11 (20%) 78 (18%) ns 1.20 (0.63 to 2.29)
IgG anti-β2GPI 9 (17%) 91 (21%) ns 0.84 (0.43 to 1.68)
IgG PT 4 (7%) 56 (13%) ns 0.69 (0.27 to 1.73)
IgG anti-CCP 4 (24%) 8 (4%) 1.39×10−2 4.56 (1.36 to 15.26)
IgG anti-CAP 2 (12%) 12 (7%) ns 1.60 (0.37 to 6.92)
ANA 115 (96%) 850 (99%) ns 0.40 (0.16 to 1.04)
anti-dsDNA 53 (61%) 421 (62%) ns 1.50 (0.17 to 13.10)
anti-Sm 14 (16%) 79 (12%) ns 0.98 (0.64 to 1.50)
Serum anti-CL, anti-β2-GPI and anti-PT were analysed in 490 patients (54 CA/CC and 436 
AA) where all have data for anti-CL IgG and anti-prothrombin, 488 patients (54 CA/CC and 
434 AA) have data for anti-CL IgM and 489 patients (53 CA/CC and 436 AA) have anti-β2-
GP1 data. Serum anti-CCP and anti-CAP were measured by ELISA in 195 patients (17 CA/
CC and 178 AA). ANA, anti-dsDNA and anti-Sm were measured according to the diagnosis 
criteria of American College of Rheumatology. Data for ANA were available from 982 
patients (120 CA/CC and 862 AA) and anti-dsDNA and anti-Sm data was available from 761 
patients (87 CA/CC and 674 AA). CA or CC indicate rs2230926 risk allele.
ANA, anti-nuclear antibodies; anti-Sm, anti-Smith antibodies; β2-GPI, β2 glycoprotein-I; CCP, 
cyclic citrullinated peptide (pos≥25 U/mL); CL, cardiolipin; dsDNA, double-stranded DNA; ns, 
non-significant; PT, prothrombin; SLE, systemic lupus erythematosus.
found a significantly increased frequency of IgG anti-CCP in the 
patients with rs2230926 allele when compared with the rest of 
the patients (24% vs 4%, table 2). This finding further indicates 
that A20 DUB-domain variant is strongly associated with protein 
citrullination and modification of immunogens in humans. A weak 
association with the occurrence of malar rash and seizures and the 
presence of rs2230926 allele was observed, whereas no other clin-
ical associations were found (online supplementary table S4).
dISCuSSIOn
In this study, we reveal a novel functional mechanism for the auto-
immunity risk mediated by the genetic disruption of A20 DUB-do-
main, that is, increased protein citrullination and extracellular trap 
formation due to upregulation of PADI4. Even though polymor-
phisms in A20 DUB region are among the most frequently reported 
risk alleles in RA and SLE, their functional impact has not been 
well established. Several studies have attributed an NF-κB-regu-
lating role to the A20 DUB domain.4 7 8 However, there is a lack 
of functional studies in human cells and the mechanistic data 
describing the role of A20 DUB activity are mainly performed in 
cell-free in vitro systems.7 8 Our data show that A20 DUB activity 
is not necessary for NF-κB inhibition in human immune cells and 
is in agreement with a recent report by De et al6 using immune cells 
from A20 C103A mice. Our data does not exclude however, that 
other reported polymorphisms in the gene of A20, such as those 
leading to decreased A20 protein levels or those affecting the A20 
zinc fingers, impact NF-κB activation.30 31
Increased NET formation have been described in SLE patients 
previously and has been connected both to autophagy and to a 
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defective clearance of NETs.32 33 Although histone H3 citrullina-
tion (H3cit), NET formation and release of nuclear antigens have 
been linked to the pathogenesis of SLE, the role of these mech-
anisms as drivers of disease phenotypes has not been clear. Our 
observations revealing a novel genetic link between SLE risk and 
protein citrullination and NET formation, provide support for this 
pathway as a disease-driving mechanism in SLE. These findings are 
consistent with studies showing that PAD inhibition is immuno-
modulatory in the murine NZM lupus model characterised by Type 
I IFNs, vascular dysfunction and prothrombotic risk, suggesting 
PAD-mediated NET formation as an upstream modulator of the 
various disease phenotypes.34 Furthermore, blocking mitochon-
drial ROS production and subsequent spontaneous NET formation 
in a mouse model of lupus resulted in reduced disease severity.35 
Admittedly, the role of NETs is challenged in other experimental 
lupus-like models, such as the MRL. Fas-lpr or pristane-induced 
models, where PADI4 deletion or Nox2 deletion (disrupting NET 
formation) failed to ameliorate the phenotype.36–38
An outstanding question still is how the mutations in the 
A20 DUB domain can regulate PADI4. Mass spectrometry data 
of proteins bound to the different A20 forms (WT, C103A and 
F127C) did not reveal any direct binding between A20 or any 
known or predicted transcription factors regulating PADI4 (data 
not shown), which may indicate that a multistep mechanism is 
involved. The lack of PADI4 upregulation in A20 KO cells and the 
fact that heterozygote individuals for rs2230926 present increased 
PADI4 levels and increased autoimmunity risk, suggest a dominant 
acquired novel function of the mutated A20. Additional studies 
are thus warranted to establish the full mechanism clarifying how 
mutated A20 DUB domain regulates PADI4 expression.
Our findings, which were unexpected, reveal a novel genetic 
alteration involved in the regulation of protein citrullination, 
proposing an explanation for the contribution of A20 DUB-do-
main polymorphisms in the autoimmune pathogenesis. The results 
presented in this study highlight protein citrullination, extracel-
lular trap formation and neutrophils as key factors in the patho-
genic process in SLE and further support PAD4 as a target for the 
prevention and treatment of this disease.
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